Publication | Closed Access

Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension

Molecular PharmacologyPulmonary Arterial HypertensionHeart FailureCardiovascular DiseaseMedicinePhysiologyVascular RemodellingCardiovascular PharmacologyPulmonary PharmacologyVascular BiologyPharmacotherapyPublic HealthPharmacologyCardiologyPulmonary Vascular Disease